特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
603630

呼吸器疾患の新しい薬剤とスマートデバイスの展望:2018-2030年

Novel Drugs and Smart Devices for Respiratory Disorders, 2018 - 2030

出版日: | 発行: Roots Analysis | ページ情報: 英文 420 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.49円
呼吸器疾患の新しい薬剤とスマートデバイスの展望:2018-2030年
出版日: 2018年02月02日
発行: Roots Analysis
ページ情報: 英文 420 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、呼吸器疾患の新しい薬剤とスマートデバイスの市場を調査し、呼吸器疾患の概要・分類・アンメットニーズ、臨床開発の動向、主な上市済み薬剤および承認済み薬剤のプロファイル、スマート吸入器の開発環境、法規制環境、新たな薬剤およびスマート吸入器の市場規模の推移と予測、市場機会の分析などをまとめています。

第1章 序章

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 呼吸器疾患と医療負担
  • 呼吸器疾患のタイプ
  • 呼吸器疾患の有病率
  • アンメットニーズの高い呼吸器疾患
    • 喘息
    • 慢性閉塞性肺疾患 (COPD)
    • 嚢胞性線維症

第4章 市場概要

  • 本章の概要
  • 呼吸器疾患パイプライン:適応症別
    • 喘息
    • COPD
    • 嚢胞性線維症
      • 開発フェーズによる分布
      • 作用機序による分布
      • 分子タイプによる分布
      • 投薬モードによる分布
      • 投薬頻度による分布
      • 企業による分布

第5章 アンメットニーズの分析

  • 本章の概要
  • アンメットニーズの分析:喘息
  • アンメットニーズの分析:COPD
  • アンメットニーズの分析:嚢胞性線維症

第6章 企業プロファイル

  • 本章の概要
  • AbbVie
  • AstraZeneca
  • Boehringer Ingelheim
  • Chiesi Pharmaceuticals
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical
  • Vertex Pharmaceuticals
  • CURx Pharmaceuticals
  • Laurent Pharmaceuticals
  • Sanofi
  • Gilead Sciences
  • AB Science

第7章 薬剤プロファイル

  • 本章の概要
  • 上市済み / 承認済み薬剤
    • LAMA / LABA併用
      • ANORO™ ELLIPTA®
      • BEVESPI AEROSPHERE®
      • Duaklir® Genuair®
      • STIOLTO™ RESPIMAT®
      • Ultibro® Breezhaler® / Utibron® Neohaler®
    • ICS / LAMA / LABA併用
      • Trelegy Ellipta
      • Trimbow™
    • IL-5阻害剤/ IgE 受容体拮抗薬
      • CINQAIR®
      • FASENRA™
      • NUCALA®
      • XOLAIR®
    • CFTR調整因子/ 新しい抗生剤
      • Bronchitol®
      • KALYDECO®
      • ORKAMBI®
  • 開発後期候補薬
    • QVM149
    • Masitinib
    • PT010
    • QAW039
    • SAR231893 / REGN668
    • Spirivia (嚢胞性線維症)
    • Timapiprant
    • VX-661・Ivacaftor併用

第8章 主な考察

  • 本章の概要
  • 喘息・COPD・嚢胞性線維症:企業規模別のパイプライン分析
  • 喘息:開発フェーズ・薬剤クラス・分子タイプ・投薬モード別のパイプライン分析
  • COPD:開発フェーズ・薬剤クラス・分子タイプ・投薬モード別のパイプライン分析
  • 嚢胞性線維症:開発フェーズ・薬剤クラス・分子タイプ・投薬モード別のパイプライン分析

第9章 スマート吸入器:イントロダクション・開発業者の環境

  • 本章の概要
  • IoT
  • 吸入器の進化
  • 吸入器・非服薬アドヒアランスのコスト
  • スマート吸入器
  • 近年の提携

第10章 スマート吸入器の法規制環境

  • 本章の概要
  • コネクテッドデバイスの台頭
  • 併用製品の承認:地域別
  • 安全性・有効性・性能を示すスマート吸入器

第11章 スマート吸入器:市場規模・市場機会の分析

  • 本章の概要
  • 予測手法・前提因子
  • 総市場の予測
    • 適応症別内訳
    • 喘息
    • COPD
  • 総市場のシェア:重症度別
    • 軽度喘息 / COPD
    • 中程度喘息 / COPD
    • 重度喘息 / COPD
  • 総市場のシェア:地域別

第12章 呼吸器疾患:新たな治療薬の市場規模・市場機会の分析

  • 本章の概要
  • 予測手法・前提因子
  • 総市場の予測
  • 総市場の内訳:適応症別
    • 喘息
    • COPD
    • 嚢胞性線維症
  • 総市場の内訳:薬剤クラス別
    • LABA / LAMA併用
    • ICS / LABA / LAMA併用
    • IL-5阻害剤
    • CRTh2拮抗薬
    • CFTR調節因子
    • その他
  • 総市場の内訳:企業別
  • 総市場の内訳:分子タイプ別
  • 総市場の内訳:投薬経路別
  • 総市場の内訳:地域別

第13章 総論

第14章 インタビュートランスクリプト

第15章 付録1:図表データ

第16章 付録2:企業・団体リスト

目次
Product Code: RA10099

According to the Forum of International Respiratory Societies, around 4 million individuals die each year due to chronic respiratory diseases. The World Health Organization (WHO) estimates the global prevalence of two of the most common chronic respiratory diseases, namely asthma and chronic obstructive pulmonary disease (COPD), to be around 335 million and 400 million patients respectively. Specifically, COPD is currently known to be the fourth leading cause of death worldwide. According to the data provided by the WHO, more than 3 million people die annually from COPD; this represents a total of 6% of the global annual deaths. Around 90% of these deaths occur in low and middle-income countries. Asthma, on the other hand, is more common in pediatric population. Asthma alone results in more than 30% of pediatric hospitalizations. Moreover, it is responsible for around 180,000 annual deaths worldwide.

In addition to asthma and COPD, other chronic respiratory disorders are also associated with high unmet needs. Specifically, the patients suffering from cystic fibrosis, which is known to have a global prevalence of 70,000, have reported median lifespan of less than 30 years. In addition, the patients suffering from cystic fibrosis are at a relatively higher risk of acquiring life threatening lung infections. The high prevalence, high rate of hospitalization and high cost of treatment for these disorders places a huge burden on the society in terms of direct healthcare costs and the loss of productivity associated with disability and premature mortality of the patients.

Although these diseases cannot be cured, government agencies and big pharma companies have made significant investments in R&D to improve disease management and address the unmet needs. These investments and development initiatives have led to the approval of several therapies, such as LAMA / LABA fixed dose combinations, ICS / LAMA / LABA fixed combinations, CFTR modulators, and novel biologics and antibiotics, which have helped improve the quality of life of patients. The industry is gradually transitioning towards the development of more targeted therapies. This shift is facilitating a scenario, wherein therapeutic strategies are changing from broad spectrum remedies to those that target individual patient segments.

Synopsis:

The ‘Novel Drugs and Smart Devices for Respiratory Disorders, 2018-2030’ report provides a comprehensive study on the current landscape of novel therapies and smart devices being evaluated for the treatment of asthma, COPD and cystic fibrosis. The field has captured the interest of several drug developers, both small and large companies. With several novel drug candidates in development, we anticipate the market to witness continued growth over the next 5-10 years. Amongst other elements, the report features:

  • A discussion on the novel therapies under development for the treatment of asthma, COPD and cystic fibrosis. The report provides information on the developers, phase of development of candidate drugs / therapies, mechanism of action, route of administration, type of molecule, type of formulation and the dose frequency of the various therapies.
  • An analysis highlighting the key unmet needs across asthma, COPD and cystic fibrosis. The study presents insights generated from real-time data on unmet needs identified from social media posts, recent publications, patient blogs and discussions of key opinion leaders.
  • An extensive review of the development portfolio and key initiatives undertaken by established players (players with approved / late-stage drug candidates). This section also provides an overview of the companies, their financial performance, recent collaborations and a comprehensive future outlook.
  • Elaborate profiles of marketed and phase III drugs; each profile features an overview of the drug, its mechanism of action, dosage information, details on the cost and sales (wherever available), clinical development plan, and key clinical trial results.
  • An assessment of the key players involved in the development of smart inhalers. It provides information on the development status of the inhalers, type of inhalers and the key collaborators. In addition, the report provides a comparative assessment of the various smart inhalers on the basis of several parameters, such as availability of Bluetooth, USB connection, reminder function and rechargeable options.
  • A discussion on the regulatory landscape for the approval of combination products (drugs and inhalers), as well as smart inhalers in different countries.
  • Detailed analysis of the key trends (for instance, relative start-up activity) in the development of novel therapies across asthma, COPD and cystic fibrosis.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. The research, analysis and insights presented in this report include potential sales of novel therapies, as well as smart inhalers that are currently marketed or are in the late stages of development. To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions with senior stakeholders in the industry. These include Antonio Anzueto (Pulmonologist, University of Texas Health Science Center), Richard Moss (Pediatric Pulmonologist, Lucile Packard Children's Hospital, Stanford University), Alex Stenzler (Founder and President, Novoteris), Dinesh Srinivasan (Director, Anthera Pharmaceuticals) and Dinu Sen (CEO, CURx Pharmaceuticals). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. Around 135 novel drug candidates are being evaluated across various stages of development for the treatment of patients suffering from asthma, COPD and cystic fibrosis. Of these, around 15 drugs have received approval / market authorization, and 72% and 17% of the candidates are being developed in clinical and preclinical stages, respectively.
  • 2. Majority of the novel drugs (38%) are being developed for the treatment of patients with asthma, while around 30% of the candidates are being developed to target COPD. Rest of the drugs are being evaluated for the treatment of cystic fibrosis. 11% of the therapies target more than one of these diseases.
  • 3. The development landscape comprises of around 90 companies and universities. Of these, around 37% of the players are small-sized companies (less than 50 employees), close to 30% of the players are mid-sized companies (51-200 employees) and around 33% are large-size players / universities (more than 200 employees.
  • 4. Of the big pharma companies, several players have recently received approval for their novel product(s) being developed for asthma, COPD and cystic fibrosis; examples of these companies are (in alphabetical order, no selection criteria) AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, Gilead Sciences, GSK, Novartis, Teva Pharmaceutical and Vertex Pharmaceuticals.
  • 5. Specifically for asthma, the industry focus is gradually shifting towards development of therapies for the treatment of patients with moderate to severe disease. In fact, in the last few years, four biologics have been approved for the treatment of severe form of asthma. These are FASENRA™ (2017), CINQAIR™ (2016), XOLAIR® (2016, for pediatric patients) and NUCALA® (2015).
  • 6. For the treatment of COPD, most of the approved novel therapies are combinations of long-acting beta-agonist (LABA) and long-acting muscarinic receptor antagonist (LAMA) drugs. Examples of marketed dual fixed dose combinations include ANORO ELLIPTA™ (2017), BEVESPI AEROSPHERE® / PT003 (2016), Utibron™ Neohaler® (2015), STIOLTO™ RESPIMAT® (2015), Duaklir® Genuair® / Brimica Genuair (2014) and Ultibro® Breezhaler® (2013).
  • 7. Across cystic fibrosis, the launch of KALYDECO® in 2012 and ORKAMBI® in 2015 by Vertex Pharmaceuticals has revolutionized the treatment landscape. Several novel combinations or drug classes are being evaluated in late stages of clinical development. Emerging targeted approaches, such as gene therapy and gene editing, are also being explored.
  • 8. A detailed analysis of the opinions expressed on patient blogs, social media posts and published literature, and by KOLs highlights significant unmet needs across asthma, COPD and cystic fibrosis. High rate of non-adherence, delayed / mis-diagnosis and lack of personalized therapies are amongst the pressing unmet needs.
  • 9. To overcome the unmet needs associated with drug adherence, the industry is promoting the use of connected devices, such as smart inhalers, that enable the patient / healthcare providers to track drug intake. In fact, we identified more than 20 companies involved in the development of smart inhalers; examples include (in alphabetical order) 3M, Adherium, Aerobit, Cohero Health, FindAir, Gecko Health Innovations, H&T Presspart, Inspiro Medical, OPKO Health, Propeller Health, Qualcomm Life, and Vectura.
  • 10. With several approved drugs and late stage clinical (phase II and above) candidates, the market for novel therapeutics is anticipated to grow at a steady pace between 2018 and 2030. By 2030, a number of LABA / LAMA, as well as ICS / LABA / LAMA fixed dose combinations, are likely to attain blockbuster status. Examples include ANORO ELLIPTA™, Utibron™ Neohaler® / Ultibro® Breezhaler®, FASENRA™ and ORKAMBI®.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the respiratory disorders market, specific to asthma, COPD and cystic fibrosis, in the short-mid and long term.

Chapter 3 provides a general introduction to asthma, COPD and cystic fibrosis. In this section, we have discussed, in detail, the healthcare burden associated with the three indications. In addition, we have provided information on the diseases, including details on the key triggers, types and symptoms, statistics, regional prevalence, current treatment options and the treatment guidelines set by regulatory authorities.

Chapter 4 provides a comprehensive overview of the market landscape of novel therapies that are approved or are being developed in clinical and preclinical stages for the treatment of patients with asthma, COPD and cystic fibrosis. This chapter includes information on the developers of these candidates, along with details on the mechanism of action, route of administration, type of molecule, type of formulation, and dose frequency of the therapies.

Chapter 5 highlights the key unmet needs associated with the management and treatment of asthma, COPD and cystic fibrosis. For each of these indications, the chapter provides detailed analysis of unmet needs that were identified from views expressed by patients / experts across different platforms, such as social media posts, recent publications and patient blogs, and the discussions of key opinion leaders at conferences / symposiums. We have analyzed the information in the form of an insightful sentiment analysis and word cloud analysis to better understand the opinions expressed across the public portals.

Chapter 6 includes detailed profiles of the players that have received approval for their novel therapies targeting asthma, COPD or cystic fibrosis. Each profile provides a brief overview of the company, its financial performance, product portfolio, recent collaborations and future outlook. In addition, each profile includes a detailed brand positioning matrix for the player covering several aspects such as pipeline strength / diversity, likely time to market, trial results, recent collaborations, accelerated designations, reimbursement agreements, and the overall market positioning of the players.

Chapter 7 contains detailed profiles of drugs that are marketed or are in phase III of development. Each profile features an overview of the drug, and provides information on the mechanism of action, dosage, cost and sales, clinical development plan, and results of the key clinical trials.

Chapter 8 features an overview of the market landscape of the key players involved in the development of smart inhalers. It provides information on the development status of the inhalers, type of inhalers and the key collaborators. In addition, the chapter presents a comparative product competitiveness analysis of the various smart inhalers on the basis of different parameters, such as availability of Bluetooth, USB connection, reminder function and rechargeable options.

Chapter 9 presents detailed analysis of the key trends observed in the development of novel therapies for asthma, COPD and cystic fibrosis. The chapter presents the landscape of various players involved in the development of therapies for respiratory disorders. Additionally, it presents four-dimensional grid analysis (based on the phase of development / mechanism of action / type of molecule / mode of administration) of the pipeline candidates against asthma, COPD and cystic fibrosis.

Chapter 10 provides information on the regulatory environment related to the grant of marketing authorizations for combination products (inhaler and drug) across different countries. It highlights the role of regulatory bodies in the approval of smart inhalers in North America, Europe, Latin America, Asia Pacific and the Middle East.

Chapter 11 presents an assessment of the market opportunity for smart inhalers. It provides detailed projections of the sales of such inhalers. The sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition and the likely price of these inhalers. The chapter also presents segmentation of the smart inhalers market on the basis of the indications (asthma, COPD and cystic fibrosis), severity (early-stage, moderate and severe) of the disease and the geographies.

Chapter 12 provides a comprehensive forecast analysis, highlighting the future potential of the respiratory disorders market, specific to asthma, COPD and cystic fibrosis, till the year 2030. It includes future sales projections of the drugs that are either marketed or are being evaluated in advanced stages of clinical development. The sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of the products. The chapter also presents a detailed market segmentation on the basis of the indications, geographies, drug classes, route of administration, and type of molecule.

Chapter 13 summarizes the overall report. The chapter provides a list of the key takeaways and presents our independent opinion on the respiratory disorders market, specific to asthma, COPD and cystic fibrosis, based on the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Antonio Anzueto (Pulmonologist, University of Texas Health Science Center), Richard Moss (Pediatric Pulmonologist, Lucile Packard Children's Hospital, Stanford University), Alex Stenzler (Founder and President, Novoteris), Dinesh Srinivasan (Director, Anthera Pharmaceuticals) and Dinu Sen (CEO, CURx Pharmaceuticals).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Respiratory Disorders and the Healthcare Burden
  • 3.2. Type of Respiratory Disorders
  • 3.3. Prevalence of Respiratory Disorders
  • 3.4. Respiratory Disorders with High Unmet Need
    • 3.4.1. Asthma
      • 3.4.1.1. Introduction
      • 3.4.1.2. Key Triggers
      • 3.4.1.3. Types and Symptoms
      • 3.4.1.4. Disease Statistics
      • 3.4.1.5. Treatment Options
      • 3.4.1.6. Economic Burden
    • 3.4.2. Chronic Obstructive Pulmonary Disease (COPD)
      • 3.4.2.1. Introduction
      • 3.4.2.2. Key Triggers
      • 3.4.2.3. Types and Symptoms
      • 3.4.2.4. Disease Statistics
      • 3.4.2.5. Treatment Options
      • 3.4.2.6. Economic Burden
    • 3.4.3. Cystic Fibrosis
      • 3.4.3.1. Introduction
      • 3.4.3.2. Key Triggers
      • 3.4.3.3. Types and Symptoms
      • 3.4.3.4. Disease Statistics
      • 3.4.3.5. Treatment Options
      • 3.4.3.6. Economic Burden

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Respiratory Disorders Pipeline: Distribution by Indication
    • 4.2.1. Asthma Pipeline
      • 4.2.1.1. Distribution by Phase of Development
      • 4.2.1.2. Distribution by Mechanism of Action
      • 4.2.1.3. Distribution by Type of Molecule
      • 4.2.1.4. Distribution by Mode of Administration
      • 4.2.1.5. Distribution by Dose Frequency
      • 4.2.1.6. Distribution by Key Players
    • 4.2.2. COPD Pipeline
      • 4.2.2.1. Distribution by Phase of Development
      • 4.2.2.2. Distribution by Mechanism of Action
      • 4.2.2.3. Distribution by Type of Molecule
      • 4.2.2.4. Distribution by Mode of Administration
      • 4.2.2.5. Distribution by Dose Frequency
      • 4.2.2.6. Distribution by Key Players
    • 4.2.3. Cystic Fibrosis Pipeline
      • 4.2.3.1. Distribution by Phase of Development
      • 4.2.3.2. Distribution by Mechanism of Action
      • 4.2.3.3. Distribution by Type OF Molecule
      • 4.2.3.4. Distribution by Mode of Administration
      • 4.2.3.5. Distribution by Dose Frequency
      • 4.2.3.6. Distribution by Key Players

5. UNMET NEED ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Unmet Need Analysis in Asthma
    • 5.2.1. Introduction
    • 5.2.2. Patient Blogs
      • 5.2.2.1. Methodology
      • 5.2.2.2. Key Insights
    • 5.2.3. Published Literature
      • 5.2.3.1. Methodology
      • 5.2.3.2. Key Insights
    • 5.2.4. Social Media Platforms
      • 5.2.4.1. Methodology
      • 5.2.4.2. Key Insights
    • 5.2.5. Expert Opinions (Source: Public Portals)
      • 5.2.5.1. Nicola Hanania, Associate Professor of Medicine, Baylor College of Medicine, US
      • 5.2.5.2. Ian Adcock, Professor of Respiratory Cell and Molecular Biology, National Heart and Lung Institute, Imperial College London, UK
      • 5.2.5.3. Nikolaos Papadopoulos, Professor of Allergy and Pediatric Allergy, Institute of Human Development, UK
      • 5.2.5.4. Antonio Spanevello, Director of the Post Graduate School in Respiratory Diseases, University of Insubria, Italy
      • 5.2.5.5. Sally Wenzel, MD, Director, University of Pittsburgh Medical Center (UPMC) Asthma Institute, US
    • 5.2.6. Summary: Key Unmet Needs in Asthma
  • 5.3. Unmet Need Analysis in COPD
    • 5.3.1. Introduction
    • 5.3.2. Patient Blogs
      • 5.3.2.1. Methodology
      • 5.3.2.2. Key Insights
    • 5.3.3. Published Literature
      • 5.3.3.1. Methodology
      • 5.3.3.2. Key Insights
    • 5.3.4. Social Media Platforms
      • 5.3.4.1. Methodology
      • 5.3.4.2. Key Insights
    • 5.3.5. Expert Opinions (Source: Public Portals)
      • 5.3.5.1. Nicholas Hart, Clinical Director, King's College London, UK
      • 5.3.5.2. Peter Barnes, Professor and Head of Respiratory Medicine, Imperial College London, UK
      • 5.3.5.3. Mario Cazzola, Director, Post Graduate School of Respiratory Medicine, University of Rome, Italy
      • 5.3.5.4. Brian Carlin, Pulmonologist, US
      • 5.3.5.5. Nikolaos Papadopoulos, Professor of Allergy and Pediatric Allergy, Institute of Human Development, UK
    • 5.3.6. Summary: Key Unmet Needs in COPD
  • 5.4. Unmet Need Analysis in Cystic Fibrosis
    • 5.4.1. Introduction
    • 5.4.2. Patient Blogs
      • 5.4.2.1. Methodology
      • 5.4.2.2. Key Insights
    • 5.4.3. Published Literature
      • 5.4.3.1. Methodology
      • 5.4.3.2. Key Insights
    • 5.4.4. Social Media Platforms
      • 5.4.4.1. Methodology
      • 5.4.4.2. Key Insights
    • 5.4.5. Key Expert Opinions (Source: Public Portals)
      • 5.4.5.1. Randall Rosenblatt, MD, Chief of Pulmonary Medicine, Baylor University Medical Center, US
      • 5.4.5.2. Multiple Speakers
      • 5.4.5.3. Kenneth Olivier, Staff Clinician, National Institute of Allergy and Infectious Diseases in Bethesda, US
      • 5.4.5.4. Kevin Southern, Pediatric Respiratory Consultant, Alder Hey Children's Hospital, UK
    • 5.4.6. Summary: Key Unmet Needs in Cystic Fibrosis

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. AbbVie
    • 6.2.1. Company Overview
    • 6.2.2. Financial Performance
    • 6.2.3. Respiratory Disorders: Development Portfolio
    • 6.2.4. Recent Collaborations
    • 6.2.5. Future Outlook
    • 6.2.6. Brand Positioning Matrix
  • 6.3. AstraZeneca
    • 6.3.1. Company Overview
    • 6.3.2. Financial Performance
    • 6.3.3. Respiratory Disorders: Development Portfolio
    • 6.3.4. Recent Collaborations
    • 6.3.5. Future Outlook
    • 6.3.6. Brand Positioning Matrix
  • 6.4. Boehringer Ingelheim
    • 6.4.1. Company Overview
    • 6.4.2. Financial Performance
    • 6.4.3. Respiratory Disorders: Development Portfolio
    • 6.4.4. Recent Collaborations
    • 6.4.5. Future Outlook
    • 6.4.6. Brand Positioning Matrix
  • 6.5. Chiesi Pharmaceuticals
    • 6.5.1. Company Overview
    • 6.5.2. Financial Performance
    • 6.5.3. Respiratory Disorders: Development Portfolio
    • 6.5.4. Recent Collaborations
    • 6.5.5. Future Outlook
    • 6.5.6. Brand Positioning Matrix
  • 6.6. GlaxoSmithKline
    • 6.6.1. Company Overview
    • 6.6.2. Financial Performance
    • 6.6.3. Respiratory Disorders: Development Portfolio
    • 6.6.4. Recent Collaborations
    • 6.6.5. Future Outlook
    • 6.6.6. Brand Positioning Matrix
  • 6.7. Novartis
    • 6.7.1. Company Overview
    • 6.7.2. Financial Performance
    • 6.7.3. Respiratory Disorders: Development Portfolio
    • 6.7.4. Recent Collaborations
    • 6.7.5. Future Outlook
    • 6.7.6. Brand Positioning Matrix
  • 6.8. Teva Pharmaceutical
    • 6.8.1. Company Overview
    • 6.8.2. Financial Performance
    • 6.8.3. Respiratory Disorders: Development Portfolio
    • 6.8.4. Recent Collaborations
    • 6.8.5. Future Outlook
    • 6.8.6. Brand Positioning Matrix
  • 6.9. Vertex Pharmaceuticals
    • 6.9.1. Company Overview
    • 6.9.2. Financial Performance
    • 6.9.3. Respiratory Disorders: Development Portfolio
    • 6.9.4. Recent Collaborations
    • 6.9.5. Future Outlook
    • 6.9.6. Brand Positioning Matrix
  • 6.10. CURx Pharmaceuticals
    • 6.10.1. Company Overview
    • 6.10.2. Financial Performance
    • 6.10.3. Respiratory Disorders: Development Portfolio
    • 6.10.4. Recent Collaborations
    • 6.10.5. Future Outlook
    • 6.10.6. Brand Positioning Matrix
  • 6.11. Laurent Pharmaceuticals
    • 6.11.1. Company Overview
    • 6.11.2. Financial Performance
    • 6.11.3. Respiratory Disorders: Development Portfolio
    • 6.11.4. Recent Collaborations
    • 6.11.5. Future Outlook
    • 6.11.6. Brand Positioning Matrix
  • 6.12. Sanofi
    • 6.12.1. Company Overview
    • 6.12.2. Financial Performance
    • 6.12.3. Respiratory Disorders: Development Portfolio
    • 6.12.4. Recent Collaborations
    • 6.12.5. Future Outlook
    • 6.12.6. Brand Positioning Matrix
  • 6.13. Gilead Sciences
    • 6.13.1. Company Overview
    • 6.13.2. Financial Performance
    • 6.13.3. Respiratory Disorders: Development Portfolio
    • 6.13.4. Recent Collaborations
    • 6.13.5. Future Outlook
    • 6.13.6. Brand Positioning Matrix
  • 6.14. AB Science
    • 6.14.1. Company Overview
    • 6.14.2. Financial Performance
    • 6.14.3. Respiratory Disorders: Development Portfolio
    • 6.14.4. Recent Collaborations
    • 6.14.5. Future Outlook
    • 6.14.6. Brand Positioning Matrix

7. DRUG PROFILES

  • 7.1. Chapter Overview
  • 7.2. Marketed / Approved Drugs
    • 7.2.1 LAMA / LABA Combinations
      • 7.2.1.1 ANORO™ ELLIPTA®
        • 7.2.1.1.1 Drug Overview
        • 7.2.1.1.2 Mechanism of Action
        • 7.2.1.1.3. Cost, Dosage and Sales
        • 7.2.1.1.4. Clinical Development
        • 7.2.1.1.5. Key Clinical Trial Results
      • 7.2.1.2. BEVESPI AEROSPHERE®
        • 7.2.1.2.1. Drug Overview
        • 7.2.1.2.2. Mechanism of Action
        • 7.2.1.2.3. Cost, Dosage and Sales
        • 7.2.1.2.4. Clinical Development
        • 7.2.1.2.5. Key Clinical Trial Results
      • 7.2.1.3. Duaklir® Genuair®
        • 7.2.1.3.1. Drug Overview
        • 7.2.1.3.2. Mechanism of Action
        • 7.2.1.3.3. Cost, Dosage and Sales
        • 7.2.1.3.4. Clinical Development
        • 7.2.1.3.5. Key Clinical Trial Results
      • 7.2.1.4. STIOLTO™ RESPIMAT®
        • 7.2.1.4.1. Drug Overview
        • 7.2.1.4.2. Mechanism of Action
        • 7.2.1.4.3. Cost, Dosage and Sales
        • 7.2.1.4.4. Clinical Development
        • 7.2.1.4.5. Key Clinical Trial Results
      • 7.2.1.5. Ultibro® Breezhaler® / Utibron® Neohaler®
        • 7.2.1.5.1. Drug Overview
        • 7.2.1.5.2. Mechanism of Action
        • 7.2.1.5.3. Cost, Dosage and Sales
        • 7.2.1.5.4. Clinical Development
        • 7.2.1.5.5. Key Clinical Trial Results
    • 7.2.2. ICS / LAMA / LABA Combinations
      • 7.2.2.1. Trelegy Ellipta
        • 7.2.2.1.1. Drug Overview
        • 7.2.2.1.2. Mechanism of Action
        • 7.2.2.1.3. Cost, Dosage and Sales
        • 7.2.2.1.4. Clinical Development
        • 7.2.2.1.5. Key Clinical Trial Results
      • 7.2.2.2. Trimbow™
        • 7.2.2.2.1. Drug Overview
        • 7.2.2.2.2. Mechanism of Action
        • 7.2.2.2.3. Cost, Dosage and Sales
        • 7.2.2.2.4. Clinical Development
        • 7.2.2.2.5. Key Clinical Trial Results
    • 7.2.3. IL-5 Inhibitors / IgE Receptor Antagonists
      • 7.2.3.1. CINQAIR®
        • 7.2.3.1.1. Drug Overview
        • 7.2.3.1.2. Mechanism of Action
        • 7.2.3.1.3. Cost, Dosage and Sales
        • 7.2.3.1.4. Clinical Development
        • 7.2.3.1.5. Key Clinical Trial Results
      • 7.2.3.2. FASENRA™
        • 7.2.3.2.1. Drug Overview
        • 7.2.3.2.2. Mechanism of Action
        • 7.2.3.2.3. Cost, Dosage and Sales
        • 7.2.3.2.4. Clinical Development
        • 7.2.3.2.5. Key Clinical Trial Results
      • 7.2.3.3. NUCALA®
        • 7.2.3.3.1. Drug Overview
        • 7.2.3.3.2. Mechanism of Action
        • 7.2.3.3.3. Cost, Dosage and Sales
        • 7.2.3.3.4. Clinical Development
        • 7.2.3.3.5. Key Clinical Trial Results
      • 7.2.3.4. XOLAIR®
        • 7.2.3.4.1. Drug Overview
        • 7.2.3.4.2. Mechanism of Action
        • 7.2.3.4.3. Cost, Dosage and Sales
        • 7.2.3.4.4. Clinical Development
        • 7.2.3.4.5. Key Clinical Trial Results
    • 7.2.4. CFTR Modulators / Novel Antibiotics
      • 7.2.4.1. Bronchitol®
        • 7.2.4.1.1. Drug Overview
        • 7.2.4.1.2. Mechanism of Action
        • 7.2.4.1.3. Cost, Dosage and Sales
        • 7.2.4.1.3. Clinical Development
        • 7.2.4.1.4. Key Clinical Trial Results
      • 7.2.4.1. KALYDECO®
        • 7.2.4.1.1. Drug Overview
        • 7.2.5.1.2. Mechanism of Action
        • 7.2.5.1.3. Cost, Dosage and Sales
        • 7.2.5.1.4. Clinical Development
        • 7.2.5.1.5. Key Clinical Trial Results
      • 7.2.4.2. ORKAMBI®
        • 7.2.4.2.1. Drug Overview
        • 7.2.4.2.2. Mechanism of Action
        • 7.2.4.2.3. Cost, Dosage and Sales
        • 7.2.4.2.4. Clinical Development
        • 7.2.4.2.5. Key Clinical Trial Results
  • 7.3. Late Stage Drug Candidates
    • 7.3.1. QVM149
    • 7.3.2. Masitinib
    • 7.3.3. PT010
    • 7.3.4. QAW039
    • 7.3.5. SAR231893 / REGN668
    • 7.3.6. Spirivia (for Cystic Fibrosis)
    • 7.3.7. Timapiprant
    • 7.3.8. VX-661 and Ivacaftor Combination

8. KEY INSIGHTS

  • 8.1. Chapter Overview
  • 8.2. Asthma, COPD and Cystic Fibrosis: Pipeline Analysis by Size of Players
  • 8.3. Asthma: Pipeline Analysis by Phase of Development, Drug Class, Type of Molecule and Mode of Administration
  • 8.4. COPD: Pipeline Analysis by Phase of Development, Drug Class, Type of Molecule and Mode of Administration
  • 8.5. Cystic Fibrosis: Pipeline Analysis by Phase of Development, Drug Class, Type of Molecule and Mode of Administration

9. SMART INHALERS: INTRODUCTION AND DEVELOPER LANDSCAPE

  • 9.1. Chapter Overview
  • 9.2. Internet of Things (IoT)
  • 9.3. Evolution of Inhalers
  • 9.4. Inhalers and The Cost of Non-Adherence
  • 9.5. Smart Inhalers
    • 9.5.1. Introduction
    • 9.5.2. Market Landscape
    • 9.5.3. Distribution by Key Parameters
      • 9.5.3.1. Bluetooth
      • 9.5.3.2. Reminders
      • 9.5.3.3. Inhaler Type
      • 9.5.3.4. Status of Development
    • 9.5.4. Smart Inhaler Developer: Brand Positioning Matrix
  • 9.5.5 Recent Collaborations
    • 9.5.6. Business Models
    • 9.5.7. Ideal Smart Inhaler
      • 9.5.7.1. Connectivity
      • 9.5.7.2. Storage
      • 9.5.7.3. Design
      • 9.5.7.4. Interface and Patient Interaction
      • 9.5.7.5. Reminders and Dose Recording
      • 9.5.7.6. Other Features

10. REGULATORY LANDSCAPE FOR SMART INHALERS

  • 10.1. Chapter Overview
  • 10.2. Rise of Connected Devices
  • 10.3. Regulatory Approval of Combination Products in the US
    • 10.3.1. Overview
    • 10.3.2. Historical Background
    • 10.3.3. Regulatory Bodies and their Role in Product Approval
    • 10.3.4. Regulatory Approval Pathway for Smart Inhalers
  • 10.4. Regulatory Approval of Combination Products in Europe
    • 10.4.1. Overview
    • 10.4.2. Regulatory Bodies and their Role in Product Approval
    • 10.4.3. Regulatory Approval Pathway for Smart Inhalers
  • 10.5. Regulatory Approval of Combination Products in Canada
    • 10.5.1. Overview
    • 10.5.2. Regulatory Bodies and their Role in Product Approval
    • 10.5.3. Regulatory Approval Pathway for Smart Inhalers
  • 10.6. Regulatory Approval of Combination Products in Brazil
    • 10.6.1. Overview
    • 10.6.2. Regulatory Bodies and their Role in Product Approval
    • 10.6.3. Regulatory Approval Pathway of Smart Inhalers
  • 10.7. Regulatory Approval of Combination Products in Mexico
    • 10.7.1. Overview
    • 10.7.2. Regulatory Bodies and their Role in Product Approval
    • 10.7.3. Regulatory Approval Pathway for Smart Inhalers
  • 10.8. Regulations of Combination Products in Argentina
    • 10.8.1. Overview
    • 10.8.2. Regulatory Bodies and their Role in Product Approval
    • 10.8.3. Regulatory Approval Pathway for Smart Inhalers
  • 10.9. Regulatory Approval of Combination Products in Australia
    • 10.9.1. Overview
    • 10.9.2. Regulatory Bodies and their Role in Product Approval
    • 10.9.3. Regulatory Approval Pathway for Smart Inhalers
  • 10.10. Regulatory Approval of Combination Products in Japan
    • 10.10.1. Overview
    • 10.10.2. Regulatory Bodies and their Role in Product Approval
    • 10.10.3. Regulatory Approval Pathway for Smart Inhalers
  • 10.11. Regulatory Approval of Combination Products in China
    • 10.11.1. Overview
    • 10.11.2. Regulatory Bodies and their Role in Product Approval
    • 10.11.3. Regulatory Approval Pathway for Smart Inhalers
  • 10.12. Regulations of Combination Products in India
    • 10.12.1. Overview
    • 10.12.2. Regulatory Bodies and their Role in Product Approval
    • 10.12.3. Regulatory Approval Pathway for Smart Inhalers
  • 10.13. Regulation of Combination Products in South Korea
    • 10.13.1. Overview
    • 10.13.2. Regulatory Bodies and their Role in Product Approval
    • 10.13.3. Regulatory Approval Pathway for Smart Inhalers
  • 10.14. Regulation of Combination Products in Saudi Arabia
    • 10.14.1. Overview
    • 10.14.2. Regulatory Bodies and their Role in Product Approval
    • 10.14.3. Regulatory Approval Pathway for Smart Inhalers
  • 10.15. Regulation of Combination Products in United Arab Emirates (UAE)
    • 10.15.1. Overview
    • 10.15.2. Regulatory Bodies and their Role in Product Approval
    • 10.15.3. Regulatory Approval Pathway for Smart Inhalers
  • 10.16. Smart Inhalers: Demonstrating Safety, Effectiveness and Performance

11. SMART INHALERS: MARKET SIZE AND OPPORTUNITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Forecast Methodology and Key Assumptions
  • 11.3. Overall Smart Inhalers Market, 2018-2030
    • 11.3.1 Overall Smart Inhalers Market: Distribution by Indication
    • 11.4.1. Smart Inhalers Market: Asthma
    • 11.4.2. Smart Inhalers Market: COPD
  • 11.5. Overall Smart Inhalers Market: Distribution by Disease Severity
    • 11.5.1. Smart Inhalers Market: Mild Asthma / COPD
    • 11.5.2. Smart Inhalers Market: Moderate Asthma / COPD
    • 11.5.3. Smart Inhalers Market: Severe Asthma / COPD
  • 11.4. Overall Smart Inhalers Market: Distribution by Geography

12. RESPIRATORY DISORDERS: NOVEL THERAPEUTICS, MARKET SIZE AND OPPORTUNITY ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Forecast Methodology and Key Assumptions
  • 12.3. Respiratory Disorders: Overall Novel Therapeutics Market, 2018-2030
  • 12.4. Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Indication
    • 12.4.1. Asthma
    • 12.4.2. COPD
    • 12.4.3. Cystic Fibrosis
  • 12.5. Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Drug Class
    • 12.5.1. LABA / LAMA Combinations
    • 12.5.2. ICS / LABA / LAMA Combinations
    • 12.5.3. IL-5 Inhibitors
    • 12.5.4. CRTh2 Antagonists
    • 12.5.5. CFTR Modulators
    • 12.5.6. Other Drug Classes
  • 12.6. Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Key Players
  • 12.7. Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Type of Molecule
  • 12.8. Respiratory Disorders: Overall Novel Therapeutics Market: Distribution by Route of Administration
  • 12.9. Respiratory Disorders: Overall Novel Therapeutics Market: Distribution by Geography

13. CONCLUSION

  • 13.1. With High Prevalence and Lack of Efficient Treatment Options, Asthma, COPD and Cystic Fibrosis Continue to Pose Enormous Burden on the Healthcare System
  • 13.2. To Improve Disease Management, Several Stakeholders, including Well Established Pharma Players, are Exploring Novel Opportunities
  • 13.3. LABA / LAMA and ICS / LAMA / LABA Fixed Dose Combinations are Redefining Treatment Options for COPD; Biologics are Expected to Become Popular for Asthma
  • 13.4. High Success of CFTR Modulators Has Offered Hope in the Cystic Fibrosis Segment; Combination Therapies are Likely to Emerge in the Near Future
  • 13.5. Despite These Advancements, High Rate of Non-adherence, Delayed / Mis-Diagnosis and Lack of Personalized Therapies are amongst the pressing Unmet Needs
  • 13.6. With Various Companies Adopting Digital Solutions to Overcome Specific Patient Needs, Smart Inhalers are Likely to Offer Significant Opportunities
  • 13.7. As the Recently Approved Therapies Provide More Evidence of their Benefits, the Overall Market is Anticipated to Grow at a Steady Pace

14. INTERVIEW TRANSCRIPTS

  • 14.1. Chapter Overview
  • 14.2. Alex Stenzler, Founder and President, Novoteris
  • 14.3 Dinu Sen, CEO, CURx Pharmaceuticals
  • 14.4 Antonio Anzueto, Pulmonologist, University of Texas Health Science Center
  • 14.5 Richard Moss, Pediatric Pulmonologist, Lucile Packard Children's Hospital, Stanford University
  • 14.6 Dinesh Srinivasan, Director, Anthera Pharmaceuticals

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1: Respiratory Disorders: Classification
  • Figure 3.2: Respiratory Disorders: Key Statistics
  • Figure 3.3: Asthma: Key Triggers
  • Figure 3.4: Asthma: Global Prevalence
  • Figure 3.5: Asthma: Treatment Options
  • Figure 3.6: Asthma: Treatment Guidelines, Global Initiative for Asthma (GINA) 2017
  • Figure 3.7: Asthma: Treatment Guidelines for Adults, UK
  • Figure 3.8: Asthma: Treatment Guidelines for Children, UK
  • Figure 3.9: Asthma: Distribution of Patients by Disease Severity
  • Figure 3.10: Asthma: Distribution of Annual Treatment Cost by Disease Severity
  • Figure 3.11: COPD: Key Statistics
  • Figure 3.12: COPD: Key Triggers
  • Figure 3.13: COPD: ABCD Assessment Framework
  • Figure 3.14: COPD: Global Prevalence
  • Figure 3.15: COPD: Distribution by Disease Severity
  • Figure 3.16: COPD: Treatment Guidelines
  • Figure 3.17: COPD: Distribution of Annual Treatment Cost by Type of Payer
  • Figure 3.18: COPD: Distribution of Direct Treatment Cost
  • Figure 3.19: Cystic Fibrosis: Genetic Relationship
  • Figure 3.20: Cystic Fibrosis: US Prevalence
  • Figure 3.21: Cystic Fibrosis: Global Prevalence
  • Figure 3.22: Cystic Fibrosis: Distribution by Type of Mutation
  • Figure 3.23: Cystic Fibrosis: Distribution by Type of Therapy (Children)
  • Figure 3.24: Cystic Fibrosis: Distribution by Primary Airway Clearance Techniques
  • Figure 3.25: Cystic Fibrosis: Distribution of Annual Treatment Cost by Disease Severity
  • Figure 3.26: Cystic Fibrosis: Distribution of Annual Treatment Cost by Type of Treatment
  • Figure 3.27: Cystic Fibrosis: Distribution of Patients by Disease Severity and Insurance Provider
  • Figure 4.1: Respiratory Disorders Pipeline: Distribution by Indication
  • Figure 4.2: Asthma Pipeline: Distribution by Phase of Development
  • Figure 4.3: Asthma Pipeline: Distribution by Mechanism of Action
  • Figure 4.4: Asthma Pipeline: Distribution by Type of Molecule
  • Figure 4.5: Asthma Pipeline: Distribution by Mode of Administration
  • Figure 4.6: Asthma Pipeline: Distribution by Dose Frequency
  • Figure 4.7: Asthma Pipeline: Distribution by Key Players
  • Figure 4.8: COPD Pipeline: Distribution by Phase of Development
  • Figure 4.9: COPD Pipeline: Distribution by Mechanism of Action
  • Figure 4.10: COPD Pipeline: Distribution by Type of Molecule
  • Figure 4.11: COPD Pipeline: Distribution by Mode of Administration
  • Figure 4.12: COPD Pipeline: Distribution by Dose Frequency
  • Figure 4.13: COPD Pipeline: Distribution by Key Players
  • Figure 4.14: Cystic Fibrosis: Distribution by Phase of Development
  • Figure 4.15: Cystic Fibrosis: Distribution by Mechanism of Action
  • Figure 4.16: Cystic Fibrosis: Distribution by Type of Molecule
  • Figure 4.17: Cystic Fibrosis: Distribution by Mode of Administration
  • Figure 4.18: Cystic Fibrosis: Distribution by Dose Frequency
  • Figure 4.19: Cystic Fibrosis: Distribution by Key Players
  • Figure 5.1: Unmet Need Analysis: Methodology Overview
  • Figure 5.2: Unmet Needs in Asthma: Word Cloud Analysis of Patient Blogs
  • Figure 5.3: Unmet Needs in Asthma: Cumulative Number of Publications, Year-wise Trend
  • Figure 5.4: Unmet Needs in Asthma: Social Media Platforms, Sentiment Analysis
  • Figure 5.5: Unmet Needs in Asthma: Social Media Analysis, Word Cloud
  • Figure 5.6: Unmet Needs in Asthma: Social Media Analysis: Negative Tweets
  • Figure 5.7: Key Unmet Needs in Asthma
  • Figure 5.8: Unmet Needs in COPD: Word Cloud Analysis of Patient Blogs
  • Figure 5.9: Unmet Needs in COPD: Cumulative Number of Publications, Year-wise Trend
  • Figure 5.10: Unmet Needs in COPD: Social Media Platforms, Sentiment Analysis
  • Figure 5.11: Unmet Needs in COPD: Social Media Analysis, Word Cloud
  • Figure 5.12: Unmet Needs in COPD: Social Media Analysis: Negative Tweets
  • Figure 5.13: Key Unmet Needs in COPD
  • Figure 5.14: Unmet Needs in Cystic Fibrosis: Word Cloud Analysis of Patient Blogs
  • Figure 5.15: Unmet Needs in Cystic Fibrosis: Cumulative Number of Publications, Year-wise Trend
  • Figure 5.16: Unmet Needs in Cystic Fibrosis: Social Media Platforms, Sentiment Analysis
  • Figure 5.17: Unmet Needs in Cystic Fibrosis: Social Media Analysis, Word Cloud
  • Figure 5.18: Unmet Needs in Cystic Fibrosis: Social Media Analysis, Negative Tweets
  • Figure 5.19: Key Unmet Needs in Cystic Fibrosis
  • Figure 6.1: AbbVie: Revenues, 2012- 2017 (USD Billion)
  • Figure 6.2: AbbVie: Brand Positioning Matrix
  • Figure 6.3: AstraZeneca: Revenues, 2012- 2017 (USD Billion)
  • Figure 6.4: AstraZeneca: Brand Positioning Matrix
  • Figure 6.5: Boehringer Ingelheim: Revenues, 2012- 2017 (EUR Billion)
  • Figure 6.6: Boehringer Ingelheim: Brand Positioning Matrix
  • Figure 6.7: Chiesi Pharmaceuticals: Revenues, 2012-2016 (EUR Billion)
  • Figure 6.8: Chiesi Pharmaceuticals: Brand Positioning Matrix
  • Figure 6.9: GSK: Revenues, 2012- 2017 (GBP Billion)
  • Figure 6.10: GSK: Segment-Wise Revenues, 2016 (GBP Billion)
  • Figure 6.11: GSK: Brand Positioning Matrix
  • Figure 6.12: Novartis: Revenues, 2012- 2017 (USD Billion)
  • Figure 6.13: Novartis: Brand Positioning Matrix
  • Figure 6.14: Teva Pharmaceutical: Revenues, 2012- 2017 (USD Billion)
  • Figure 6.15: Teva Pharmaceutical: Brand Positioning Matrix
  • Figure 6.16: Vertex Pharmaceuticals: Revenues, 2012- 2017 (USD Billion)
  • Figure 6.17: Vertex Pharmaceuticals: Brand Positioning Matrix
  • Figure 6.18: CURx Pharmaceuticals: Brand Positioning Matrix
  • Figure 6.19: Laurent Pharmaceuticals: Brand Positioning Matrix
  • Figure 6.20: Sanofi: Revenues, 2012- 2017 (EUR Billion)
  • Figure 6.21: Sanofi: Brand Positioning Matrix
  • Figure 6.22: Gilead Sciences: Revenues, 2012- 2017 (USD Billion)
  • Figure 6.23: Gilead Sciences: Brand Positioning Matrix
  • Figure 6.24: AB Science: Revenues, 2012- 2017 (EUR Million)
  • Figure 6.25: AB Science: Brand Positioning Matrix
  • Figure 7.1: ANORO™ ELLIPTA®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 7.2: BEVESPI AEROSPHERE®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 7.3: Duaklir®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 7.4: STIOLTO™ RESPIMAT®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 7.5: Ultibro® Breezhaler®: Annual Sales (2014- 2017, USD Million)
  • Figure 7.6: Ultibro® Breezhaler® / Utibron® Neohaler®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 7.7: Trelegy Ellipta: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 7.8: Trimbow™: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 7.9: CINQAIR®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 7.10: FASENRA™: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 7.11: NUCALA®: Annual Sales (2012-2017, GBP Million)
  • Figure 7.12: NUCALA®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 7.13: XOLAIR®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 7.14: Bronchitol®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 7.16: KALYDECO®: Annual Sales (2012- 2017, USD Million)
  • Figure 7.17: KALYDECO®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 7.18: ORKAMBI®: Annual Sales (2012- 2017, USD Million)
  • Figure 7.19: ORKAMBI®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Figure 8.1: Internet of Things: Framework
  • Figure 8.2: Internet of Things: Applications in Healthcare
  • Figure 8.3: Inhalers: Evolutionary Landscape
  • Figure 8.4: Smart Inhalers: Design and Functioning
  • Figure 8.5: Smart Inhalers: Potential Applications
  • Figure 8.6: Smart Inhalers: Distribution by Bluetooth Option
  • Figure 8.7: Smart Inhalers: Distribution by Reminder Option
  • Figure 8.8: Smart Inhalers: Distribution by Type of Inhaler
  • Figure 8.9: Smart Inhalers: Distribution by Status of Development
  • Figure 8.10: Smart Inhalers: Brand Positioning Matrix
  • Figure 8.11: Smart Inhalers: Recent Collaborations
  • Figure 8.12: Smart Inhalers: Market Opportunity
  • Figure 8.13: Ideal Smart Inhaler: Key Features
  • Figure 9.1: Asthma, COPD and Cystic Fibrosis: Pipeline Analysis by Size of Players
  • Figure 9.2: Asthma: Pipeline Analysis by Phase of Development, Drug Class, Type of Molecule and Mode of Administration
  • Figure 9.3: COPD: Pipeline Analysis by Phase of Development, Drug Class, Type of Molecule and Mode of Administration
  • Figure 9.4: Cystic Fibrosis: Pipeline Analysis by Phase of Development, Drug Class, Type of Molecule and Mode of Administration
  • Figure 10.1: Global Regulations Related to Smart Inhalers
  • Figure 10.2: Smart Inhalers: Business Models
  • Figure 10.3: Regulatory Approval Pathway for Combination Products in the US
  • Figure 10.4: Regulatory Approval Pathway for Combination Products in Canada
  • Figure 10.5: Regulatory Approval Pathway of Combination Products in China
  • Figure 11.1: Overall Smart Inhalers Market, 2018-2030, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Billion)
  • Figure 11.2: Smart Inhalers Market: Asthma, 2018-2030, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Billion)
  • Figure 11.3: Smart Inhalers Market: COPD, 2018-2030, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Billion)
  • Figure 11.4: Smart Inhalers Market: Distribution by Asthma Severity, Base Scenario, 2018, 2025 and 2030 (USD Billion)
  • Figure 11.5: Smart Inhalers Market: Distribution by COPD Severity, Base Scenario, 2018, 2025 and 2030 (USD Billion)
  • Figure 11.6: Smart Inhalers Market: Distribution by Geography, Base Scenario, 2018, 2025 and 2030 (USD Billion)
  • Figure 12.1: Respiratory Disorders: Overall Novel Therapeutics Market, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Figure 12.2: Respiratory Disorders: Novel Therapeutics Market, Asthma, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Figure 12.3: Respiratory Disorders: Novel Therapeutics Market, COPD, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Figure 12.4: Respiratory Disorders: Novel Therapeutics Market, Cystic Fibrosis, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Figure 12.5: Respiratory Disorders: Overall Novel Therapeutics Market, Market Attractiveness Analysis by Drug Class, 2018-2030 (USD Billion)
  • Figure 12.6: Respiratory Disorders: Novel Therapeutics Market, LABA / LAMA, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Figure 12.7: Respiratory Disorders: Novel Therapeutics Market, ICS / LABA / LAMA, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Figure 12.8: Respiratory Disorders: Novel Therapeutics Market, IL-5 Inhibitors, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Figure 12.9: Respiratory Disorders: Novel Therapeutics Market, CRTh2 Antagonists, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Figure 12.10: Respiratory Disorders: Novel Therapeutics Market, CFTR Modulators, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Figure 12.11: Respiratory Disorders: Novel Therapeutics Market, Other Drug Classes, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Figure 12.12: Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Key Players, 2018, 2025 and 2030
  • Figure 12.13: Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Type of Molecule, 2018, 2025 and 2030
  • Figure 12.14: Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Route of Administration, 2018, 2025 and 2030
  • Figure 12.15: Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Geography, 2018, 2025 and 2030
  • Figure 13.1: Respiratory Disorders: Overall Novel Therapeutics Market, Conservative, Base and Optimistic Forecast Scenarios, 2018, 2025 and 2030 (USD Billion)

List of Tables

  • Table 4.1: Asthma: Development Pipeline
  • Table 4.2: Asthma: Development Pipeline (Information on Type of Molecule, Dosage and Administration)
  • Table 4.3: COPD: Development Pipeline
  • Table 4.4: COPD: Development Pipeline (Information on Type of Molecule, Dosage and Administration)
  • Table 4.5: Cystic Fibrosis: Development Pipeline
  • Table 4.6: Cystic Fibrosis: Development Pipeline (Information on Type of Molecule, Dosage and Administration)
  • Table 6.1: AbbVie: Respiratory Disorders, Development Portfolio
  • Table 6.2: AstraZeneca: Respiratory Disorders, Development Portfolio
  • Table 6.3: Boehringer Ingelheim: Respiratory Disorders, Development Portfolio
  • Table 6.4: Chiesi Pharmaceuticals: Respiratory Disorders, Development Portfolio
  • Table 6.5: GlaxoSmithKline: Respiratory Disorders, Development Portfolio
  • Table 6.6: Novartis: Respiratory Disorders, Development Portfolio
  • Table 6.7: Teva Pharmaceutical: Respiratory Disorders, Development Portfolio
  • Table 6.8: Teva Pharmaceutical: Smart Inhaler Collaborations
  • Table 6.9: Vertex Pharmaceuticals: Respiratory Disorders, Development Portfolio
  • Table 6.10: CURx Pharmaceuticals: Respiratory Disorders, Development Portfolio
  • Table 6.11: Laurent Pharmaceuticals: Respiratory Disorders, Development Portfolio
  • Table 6.12: Sanofi: Respiratory Disorders, Development Portfolio
  • Table 6.13: Gilead Sciences: Respiratory Disorders, Development Portfolio
  • Table 6.14: AB Science: Respiratory Disorders, Development Portfolio
  • Table 7.1: List of Drugs: Detailed Profiles
  • Table 7.2: List of Drugs: Brief Profiles
  • Table 7.3: ANORO ELLIPTA™: Registered Clinical Trials
  • Table 7.4: BEVESPI AEROSPHERE®: Registered Clinical Trials
  • Table 7.5: Duaklir®: Registered Clinical Trials
  • Table 7.6: STIOLTO™ RESPIMAT®: Registered Clinical Trials
  • Table 7.7: Ultibro® Breezhaler® / / Utibron® Neohaler®: Registered Clinical Trials
  • Table 7.8: Trelegy Ellipta: Registered Clinical Trials
  • Table 7.9: Trimbow™: Registered Clinical Trials
  • Table 7.10: CINQAIR®: Registered Clinical Trials
  • Table 7.11: FASENRA™: Registered Clinical Trials
  • Table 7.12: NUCALA®: Registered Clinical Trials
  • Table 7.13: XOLAIR®: Dosage Regimen Every Four Weeks (Patients > 12 Years of Age)
  • Table 7.14: XOLAIR®: Dosage Regimen Every Two Weeks (Patients > 12 Years of Age)
  • Table 7.15: XOLAIR®: Dosage Regimen Every Two / Four Weeks (Patients 6-12 Years of Age)
  • Table 7.16: XOLAIR®: Registered Clinical Trials
  • Table 7.17: Bronchitol®: Registered Clinical Trials
  • Table 7.18: KALYDECO®: Registered Clinical Trials
  • Table 7.19: ORKAMBI®: Registered Clinical Trials
  • Table 7.20: Drug Profile: HCP 1202
  • Table 7.21: Drug Profile: Masitinib
  • Table 7.22: Drug Profile: PT-010
  • Table 7.23: Drug Profile: QVM149
  • Table 7.24: Drug Profile: QAW039
  • Table 7.25: Drug Profile: SAR231893 / REGN668
  • Table 7.26: Drug Profile: Spiriva
  • Table 7.27: Drug Profile: Timapiprant
  • Table 7.28: Drug Profile: VX-661 and Ivacaftor combination
  • Table 8.1: Asthma and COPD: Type of Inhalers
  • Table 8.2: Smart Inhalers: Developer Landscape
  • Table 8.3: Smart Inhalers: Information on Features
  • Table 8.4: USFDA Centers for Drugs and Device Approval
  • Table 8.5: USFDA: Review Timelines
  • Table 8.6: Regulatory Bodies in EU5 Countries
  • Table 8.7: Saudi Arabia: Regulatory Review Timeline
  • Table 15.1: Asthma: Global Prevalence
  • Table 15.2: Asthma: Distribution of Patients by Disease Severity
  • Table 15.3: Asthma: Distribution of Annual Treatment Cost by Disease Severity
  • Table 15.4: COPD: Global Prevalence
  • Table 15.5: COPD: Distribution by Disease Severity
  • Table 15.6: COPD: Distribution of Annual Treatment Cost by Type of Payer
  • Table 15.7: COPD: Distribution of Direct Cost
  • Table 15.8: Cystic Fibrosis: US Prevalence
  • Table 15.9: Cystic Fibrosis: Distribution by Type of Mutation, UK
  • Table 15.10: Cystic Fibrosis: Distribution by Type of Therapy (Children)
  • Table 15.11: Cystic Fibrosis: Distribution by Primary Airway Clearance Techniques
  • Table 15.12: Cystic Fibrosis: Distribution of Annual Treatment Cost by Disease Severity
  • Table 15.13: Cystic Fibrosis: Distribution of Annual Treatment Cost by Type of Treatment
  • Table 15.14: Cystic Fibrosis: Distribution of Patients by Disease Severity and Insurance Provider
  • Table 15.15: Respiratory Disorders Pipeline: Distribution by Indication
  • Table 15.16: Asthma Pipeline: Distribution by Phase of Development
  • Table 15.17: Asthma Pipeline: Distribution by Mechanism of Action
  • Table 15.18: Asthma Pipeline: Distribution by Type of Molecule
  • Table 15.19: Asthma Pipeline: Distribution by Mode of Administration
  • Table 15.20: Asthma Pipeline: Distribution by Dose frequency
  • Table 15.21: Asthma Pipeline: Distribution by Key Players
  • Table 15.22: COPD Pipeline: Distribution by Phase of Development
  • Table 15.23: COPD Pipeline: Distribution by Mechanism of Action
  • Table 15.24: COPD Pipeline: Distribution by Type of Molecule
  • Table 15.25: COPD Pipeline: Distribution by Mode of Administration
  • Table 15.26: COPD Pipeline: Distribution by Dose frequency
  • Table 15.27: COPD Pipeline: Distribution by Key Players
  • Table 15.28: Cystic Fibrosis Pipeline: Distribution by Phase of Development
  • Table 15.29: Cystic Fibrosis Pipeline: Distribution by Mechanism of Action
  • Table 15.30: Cystic Fibrosis Pipeline: Distribution by Type of Molecule
  • Table 15.31: Cystic Fibrosis Pipeline: Distribution by Mode of Administration
  • Table 15.32: Cystic Fibrosis Pipeline: Distribution by Dose frequency
  • Table 15.33: Cystic Fibrosis Pipeline: Distribution by Key Players
  • Table 15.34: Asthma Unmet Needs: Cumulative Number of Publications, Year-wise Trend
  • Table 15.35: COPD Unmet Needs: Cumulative Number of Publications, Year-wise Trend
  • Table 15.36: Cystic Fibrosis Unmet Needs: Cumulative Number of Publications, Year-wise Trend
  • Table 15.37: AbbVie: Revenues, 2012- 2017 (USD Billion)
  • Table 15.38: AstraZeneca: Revenues, 2012- 2017 (USD Billion)
  • Table 15.39: Boehringer Ingelheim: Revenues, 2012- 2017 (EUR Billion)
  • Table 15.40: Chiesi Pharmaceuticals: Revenues, 2012- 2016 (EUR Billion)
  • Table 15.41: GSK: Revenues, 2012- 2017 (GBP Billion)
  • Table 15.42: GSK: Segment-Wise Revenues, 2016 (GBP Billion)
  • Table 15.43: Novartis: Revenues, 2012- 2017 (USD Billion)
  • Table 15.44: Teva Pharmaceutical: Revenues, 2012- 2017 (USD Billion)
  • Table 15.45: Vertex Pharmaceuticals: Revenues, 2012- 2017 (USD Billion)
  • Table 15.46: Sanofi: Revenues, 2012- 2017 (EUR Billion)
  • Table 15.47: Gilead Sciences: Revenues, 2012 - 2017 (USD Billion)
  • Table 15.48: AB Science: Revenues, 2012 - 2017 (EUR Million)
  • Table 15.49: ANORO™ ELLIPTA®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.50: BEVESPI AEROSPHERE®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.51: Duaklir®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.52: STIOLTO™ RESPIMAT®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.53: Ultibro® Breezhaler®: Annual Sales (2014- 2017, USD Million)
  • Table 15.54: Ultibro® Breezhaler® / Utibron® Neohaler®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.55: Trelegy Ellipta: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.56: Trimbow™: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.57: CINQAIR®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.58: FASENRA™: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.59: NUCALA®: Annual Sales (2012- 2017, GBP Million)
  • Table 15.60: NUCALA®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.61: XOLAIR®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.62: Bronchitol®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.63: KALYDECO®: Annual Sales (2012- 2017, USD Million)
  • Table 15.64: KALYDECO®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.65: ORKAMBI®: Annual Sales (2012- 2017, USD Million)
  • Table 15.66: ORKAMBI®: Distribution of Clinical Trials by Phase of Development and Recruitment Status
  • Table 15.67: Smart Inhalers: Distribution by Bluetooth Option
  • Table 15.68: Smart Inhalers: Distribution by Reminders Option
  • Table 15.69: Smart Inhalers: Distribution by Type of Inhaler
  • Table 15.70: Smart Inhalers: Distribution by Status of Development
  • Table 15.71: Asthma: Four-Dimensional Grid Analysis
  • Table 15.72: COPD: Four-Dimensional Grid Analysis
  • Table 15.73: Cystic Fibrosis: Four-Dimensional Grid Analysis
  • Table 15.74: Overall Smart Inhalers Market, 2018-2030, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 15.75: Smart Inhalers Market: Asthma, 2018-2030, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 15.76: Smart Inhalers Market: COPD, 2018-2030, Conservative Scenario, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 15.77: Smart Inhalers Market: Distribution by Asthma Severity, Base Scenario, 2018, 2025 and 2030 (USD Billion)
  • Table 15.78: Smart Inhalers Market: Distribution by COPD Severity, Base Scenario, 2018, 2025 and 2030 (USD Billion)
  • Table 15.79: Smart Inhalers Market: Distribution by Geography, Base Scenario, 2018, 2025 and 2030 (USD Billion)
  • Table 15.80: Respiratory Disorders: Overall Novel Therapeutics Market, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 15.81: Respiratory Disorders: Novel Therapeutics Market, Asthma, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 15.82: Respiratory Disorders: Novel Therapeutics Market, COPD, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 15.83: Respiratory Disorders: Novel Therapeutics Market, Cystic Fibrosis, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 15.84: Respiratory Disorders: Overall Novel Therapeutics Market, Market Attractiveness Analysis by Drug Class, 2018-2030 (USD Billion)
  • Table 15.85: Respiratory Disorders: Novel Therapeutics Market, LABA / LAMA, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 15.86: Respiratory Disorders: Novel Therapeutics Market, ICS / LABA / LAMA, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 15.87: Respiratory Disorders: Novel Therapeutics Market, IL-5 Inhibitors, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 15.88: Respiratory Disorders: Novel Therapeutics Market, CRTh2 Antagonists, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 15.89: Respiratory Disorders: Novel Therapeutics Market, CFTR Modulators, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 15.90: Respiratory Disorders: Novel Therapeutics Market, Other Drug Classes, 2018-2030, Conservative Scenarios, Base Scenario and Optimistic Scenario (USD Billion)
  • Table 15.91: Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Key Players, 2018, 2025 and 2030
  • Table 15.92: Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Type of Molecule, 2018, 2025 and 2030
  • Table 15.93: Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Route of Administration, 2018, 2025 and 2030
  • Table 15.94: Respiratory Disorders: Overall Novel Therapeutics Market, Distribution by Geography, 2018, 2025 and 2030
  • Table 15.95: Respiratory Disorders: Overall Novel Therapeutics Market, Conservative, Base and Optimistic Forecast Scenarios, 2018, 2025 and 2030 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report:

  • 1. 3M
  • 2. AB Science
  • 3. AbbVie
  • 4. Abeome
  • 5. Ablynx
  • 6. Adherium
  • 7. Aerobit
  • 8. Afimmune
  • 9. Airnest
  • 10. AlgiPharma
  • 11. Almirall
  • 12. Alphabet
  • 13. American College of Chest Physicians
  • 14. American Thoracic Society
  • 15. Amgen
  • 16. Amiko
  • 17. AnaptysBio
  • 18. Anthem
  • 19. Anthera
  • 20. Aptar Pharma
  • 21. Aridis Pharmaceuticals
  • 22. Ario Pharma
  • 23. Array BioPharma
  • 24. Artax Biopharma
  • 25. ASLAN Pharmaceuticals
  • 26. Asthma UK
  • 27. AstraZeneca
  • 28. Atopix Therapeutics
  • 29. Australian Advisory Committee on Prescription Medicines
  • 30. Axikin Pharmaceuticals
  • 31. Bayer
  • 32. BIOCORP
  • 33. Biomarck Pharmaceuticals
  • 34. BioMed X
  • 35. Boehringer Ingelheim
  • 36. British Lung Foundation
  • 37. Celtaxsys
  • 38. Chiesi Pharmaceuticals
  • 39. Cipla
  • 40. Circassia Pharmaceuticals
  • 41. Cohero Health
  • 42. Concert Pharmaceuticals
  • 43. Corbus Pharmaceuticals
  • 44. CRISPR Therapeutics
  • 45. Crux Product Design
  • 46. CURx Pharmaceuticals
  • 47. Cystic Fibrosis Foundation
  • 48. Dermira
  • 49. DS Biopharma
  • 50. Duke-NUS Academic Medical Centre
  • 51. Dynavax
  • 52. Editas Medicine
  • 53. Eleventa
  • 54. Ethris
  • 55. Eularis
  • 56. European Respiratory Society
  • 57. EURRUS Biotech
  • 58. Express Scripts
  • 59. FindAir
  • 60. Five Prime Therapeutics
  • 61. Flatley Discovery Lab
  • 62. Folium Optics
  • 63. Foresee Pharmaceuticals
  • 64. Forum of International Respiratory Societies
  • 65. Galapagos
  • 66. Gecko Health Innovations
  • 67. Geisinger
  • 68. Genzyme
  • 69. Gilead Sciences
  • 70. GlaxoSmithKline (GSK)
  • 71. Glenmark Pharmaceuticals
  • 72. Global Initiative for Asthma (GINA)
  • 73. Global Initiative for Chronic Obstructive Lung Disease
  • 74. Grifols
  • 75. Guangzhou Medical University
  • 76. H&T Presspart
  • 77. Hanmi Pharmaceutical
  • 78. Health Care Originals
  • 79. Health Factors
  • 80. HealthCore
  • 81. Hewlett Packard Labs
  • 82. Hikma Pharmaceuticals
  • 83. Hydra Biosciences
  • 84. IBM
  • 85. ID Pharma
  • 86. Imperial College London
  • 87. Innoviva
  • 88. Insmed
  • 89. Inspiro Medical
  • 90. International Federation of Pharmaceutical Manufacturers and Associations
  • 91. Inventiva
  • 92. Ivax
  • 93. Janssen Biotech
  • 94. Japanese Ministry of Health, Labour and Welfare
  • 95. Jvion
  • 96. KBP Biosciences
  • 97. Koronis BioMedical Technologies
  • 98. Laurent Pharmaceuticals
  • 99. Ligand Pharmaceuticals
  • 100. Mariposa Health
  • 101. MedImmune
  • 102. Merck
  • 103. MicroDose Therapeutx
  • 104. Moderna Therapeutics
  • 105. MorphoSys
  • 106. Mylan
  • 107. National Health Service (NHS)
  • 108. NIHR Manchester Biomedical Research Centre
  • 109. Novartis
  • 110. Novimmune
  • 111. Novoclem Therapeutics
  • 112. Novoteris
  • 113. Ono Pharmaceuticals
  • 114. OPKO Health
  • 115. Orexo
  • 116. Palobiofarma
  • 117. Panmira Pharmaceuticals
  • 118. Paranta Biosciences
  • 119. Parion Sciences
  • 120. Pearl Therapeutics
  • 121. Pfizer
  • 122. Pharmaxis
  • 123. Pieris Pharmaceuticals
  • 124. Polyphor
  • 125. Propeller Health
  • 126. ProQR Therapeutics
  • 127. Proteostasis Therapeutics
  • 128. Pulmagen Therapeutics
  • 129. Pulmatrix
  • 130. Qualcomm
  • 131. Reata Pharmaceuticals
  • 132. Regeneron Pharmaceuticals
  • 133. Resolve Digital Health
  • 134. RespiVert
  • 135. REX Medical
  • 136. Rigel Pharmaceuticals
  • 137. Roche
  • 138. Sanofi
  • 139. Savara Pharmaceuticals
  • 140. Singapore Health Services (SingHealth)
  • 141. Southern Research
  • 142. Spyryx Biosciences
  • 143. Sterna Biologicals
  • 144. Sunovion
  • 145. Sunrise Labs
  • 146. Synairgen
  • 147. Syqe Medical
  • 148. Teijin Pharma
  • 149. Teva Pharmaceutical
  • 150. Therapeutics Good Administration (TGA)
  • 151. University of California Berkeley (UCB)
  • 152. University of Iowa
  • 153. US Food and Drug Administration
  • 154. Vectura
  • 155. Verona Pharma
  • 156. Vertex Pharmaceuticals
  • 157. Weill Cornell Medicine
  • 158. World Health Organization
  • 159. Xencor
  • 160. YUNGJIN Pharmaceutical
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.